Patents Assigned to Schering Corporations
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: 7592316
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: September 22, 2009
    Assignee: Schering Corporation
    Inventors: F. George Njoroge, Ashok Arasappan, Srikanth Venkatraman, Stephane L. Bogen, Kevin X. Chen, Frank Bennett
  • Peptide viral entry inhibitors
    Patent number: 7592315
    Abstract: The present invention provides, inter alia, peptide compositions and methods for treating and preventing Flaviviridae virus (e.g., hepatitis C virus) infections.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: September 22, 2009
    Assignee: Schering Corporation
    Inventors: Rong Liu, Rumin Zhang, Rong Kong
  • Farnesyl protein transferase inhibitors and their use to treat cancer
    Patent number: 7585864
    Abstract: Disclosed are compounds of the formula: wherein R8 represents a cyclic and acyclic moiety to which is bound an imidazolylalkyl group; R9 represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: September 8, 2009
    Assignee: Schering Corporation
    Inventor: Dinanath F. Rane
  • Mammalian CXC chemokine antibodies
    Patent number: 7585502
    Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: September 8, 2009
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Devora L. Rossi, Kevin B. Bacon, J. Fernando Bazan, Thomas J. Schall, Albert Zlotnik
  • Enantioselective process
    Patent number: 7582763
    Abstract: An enantioselective process for preparing intermediates useful in the preparation of the chiral tricyclic compound of formula I is disclosed.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: September 1, 2009
    Assignee: Schering Corporation
    Inventors: Frank Xing Chen, Yee-Shing Wong, Feng Liang, Marc Poirier, George Wu
  • USE OF PEGYLATED IL-10 TO TREAT CANCER
    Publication number: 20090214471
    Abstract: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.
    Type: Application
    Filed: May 11, 2009
    Publication date: August 27, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Martin Oft, Catherine Sheppard, John Mumm, Lingling Wu
  • Mammalian cytokines; related reagents
    Patent number: 7579440
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: August 25, 2009
    Assignee: Schering Corporation
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • Imidazopyrazines as cyclin dependent kinase inhibitors
    Patent number: 7576085
    Abstract: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: August 18, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Lianyun Zhao, Patrick J. Curran, David B. Belanger, Blake Hamann, Panduranga A. Reddy, M. Arshad Siddiqui
  • Methods of treating cutaneous ulcers and grafts using IL-23
    Patent number: 7575741
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: August 18, 2009
    Assignee: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Jason R. Chan
  • 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
    Patent number: 7572802
    Abstract: The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: August 11, 2009
    Assignee: Schering Corporation
    Inventors: Craig D. Boyle, Samuel Chackalamannil, Unmesh Shah, Jean E. Lachowicz
  • Mammalian cytokines; receptors; related reagents and methods
    Patent number: 7569224
    Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: August 4, 2009
    Assignee: Schering Corporation
    Inventors: Pedro A. Reche-Gallardo, Vassili Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
  • Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates for salts thereof
    Patent number: 7569705
    Abstract: In one embodiment, the present application relates to a process of making a compound of formula I. and to certain intermediate compounds that are made within the process of making the compound of formula I.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: August 4, 2009
    Assignee: Schering Corporation
    Inventors: Jeonghan Park, Anantha R Sudhakar, George S. K. Wong, Minzhang Chen, Juergen Weber, Xiaojing Yang, Daw-long Kwok, Ingyu Jeon, Ramani R Raghavan, Maria Tamarez, Weidong Tong, Eugene J. Vater
  • Method for making ?-secretase co-crystals complexed with a ligand
    Patent number: 7569391
    Abstract: The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of ?-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding human BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: August 4, 2009
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Bruce A. Malcolm, Corey O. Strickland, Wenyan Wang, Eileen Wilson
  • Human Niemann Pick C1-Like 1 Gene (NPC1L1) Polymorphisms and Methods of Use Thereof
    Publication number: 20090192135
    Abstract: The present invention relates to the identification and use of single nucleotide polymorphisms and haplotypes in the Niemann Pick C1-Like 1 (NPC1L1) gene. In particular, methods are provided for correlating NPC1L1 polymorphisms and haplo-types with the responsiveness of a pharmaceutically active compound administered to a human subject. The invention further relates to a method for estimating the responsiveness of a pharmaceutically active compound administered to a human subject which method comprises determining at least one polymorphism in the NPC1L1 gene. The methods are based on determining polymorphisms in the NPC1L1 gene and correlating the responsiveness of a pharmaceutically active compound in the human by reference to one or more polymorphism in NPC1L1.
    Type: Application
    Filed: March 28, 2006
    Publication date: July 30, 2009
    Applicants: SCHERING CORPORATION, MERCK & CO., INC., ROSETTA INPHARMATICS LLC
    Inventors: Jason Samuel Simon, Maha Chabhar Karnoub, Michael E. Severino, David James Devlin, Andrew Stewart Plump, Eric E. Schadt
  • Mammalian Cytokines; Related Reagents
    Publication number: 20090191569
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: March 30, 2009
    Publication date: July 30, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
    Patent number: 7566718
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: July 28, 2009
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Michael K. C. Wong, Youheng Shu, Wensheng Yu, Stuart B. Rosenblum, Joseph A. Kozlowski, Brian F. McGuinness, Yuefei Shao, Douglas W. Hobbs
  • Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
    Patent number: 7563801
    Abstract: Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro [4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: July 21, 2009
    Assignee: Schering Corporation
    Inventors: Zhihui Qiu, Larisa Reyderman
  • Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
    Patent number: 7563798
    Abstract: In its many embodiments, the present invention provides a class of pyrazolo [1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: July 21, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, M. Arshad Siddiqui, Panduranga Adulla P. Reddy, David B. Belanger, Blake Hamann, Patrick J. Curran
  • IL-33 receptor
    Patent number: 7560530
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: July 14, 2009
    Assignee: Schering Corporation
    Inventors: Alissa A. Chackerian, Robert A. Kastelein
  • Methods and therapeutic combinations for the treatment of demyelination
    Patent number: 7560449
    Abstract: The present invention provides methods for treating demyelination and associated conditions by administering at least one sterol absorption inhibitor and compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one demyelination treatment which can be useful for preventing or treating demyelination and associated conditions, such as multiple sclerosis.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: July 14, 2009
    Assignee: Schering Corporation
    Inventors: Jay S. Fine, Eric McFee Parker